{{Rsnum
|rsid=9024
|Gene=AP000688.14
|Chromosome=21
|position=36073015
|Orientation=plus
|GMAF=0.1313
|Gene_s=AP000688.14,CBR1
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 0.9 | 20.0 | 79.1
| HCB | 2.2 | 33.3 | 64.4
| JPT | 8.2 | 45.5 | 46.4
| YRI | 0.0 | 1.4 | 98.6
| ASW | 0.0 | 3.7 | 96.3
| CHB | 2.2 | 33.3 | 64.4
| CHD | 4.6 | 25.0 | 70.4
| GIH | 1.0 | 35.4 | 63.6
| LWK | 0.0 | 8.2 | 91.8
| MEX | 0.0 | 0.0 | 0.0
| MKK | 0.0 | 0.6 | 99.4
| TSI | 3.0 | 15.2 | 81.8
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs9024
|Name_s=
|Gene_s=CBR1, SETD4
|Feature=
|Evidence=PubMed ID:19016765
|Annotation=patients with ref GG genotype had significantly higher clearance of doxorubicin compared to GA patients, 24.42 CL/BSA vs 20.43 CL/BSA (P=0.009); patients with GG genotype hadlower exposure levels vs GA patients, 15.62 AUC/dose/BSA vs 22.43 AUC/dose/BSA (P=0.024); patients with ref GG genotype had lower peak plasma concentration of doxorubicinol compared to GA patients 0.32 Cmax/dose/BSA vs 0.48 Cmas/dose/BSA (P=0.030) ; study population: patients with invasive breast cancer; study size=62; ethnicity Chinese (74%), Malays (18%) and Indians (8%);
|Drugs=doxorubicin
|Drug Classes=
|Diseases=
|Curation Level=Curated
|PharmGKB Accession ID=PA165363188
}}

{{PharmGKB
|RSID=rs9024
|Name_s=CBR1:1096G>A
|Gene_s=CBR1, SETD4
|Feature=
|Evidence=PubMed ID:19022938
|Annotation=Risk or phenotype-associated allele: A. Phenotype: Livers with the AA genotype had twofold lower activity compared to the GG genotype as measured by production of DOXol. See dataset PA163518916 for primary data. Study population/ethnicity: Livers from Black and White donors. Significance metric(s): p = 0.02. Type of association: FA.
|Drugs=doxorubicin
|Drug Classes=
|Diseases=
|Curation Level=Curated
|PharmGKB Accession ID=PA165291919
}}

{{PMID Auto
|PMID=17267408
|Title=Allelic imbalance in gene expression as a guide to cis-acting regulatory single nucleotide polymorphisms in cancer cells.
|OA=1
}}

{{PMID Auto
|PMID=20729274
|Title=Expression of the anthracycline-metabolizing enzyme carbonyl reductase 1 in hearts from donors with Down syndrome.
|OA=1
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs9024
|overall_frequency_n=14
|overall_frequency_d=128
|overall_frequency=0.109375
|n_genomes=10
|n_genomes_annotated=0
|n_haplomes=11
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{PMID Auto
|PMID=23133646
|Title=MicroRNAs Differentially Regulate Carbonyl Reductase 1 (CBR1) Gene Expression Dependent on the Allele Status of the Common Polymorphic Variant rs9024
|OA=1
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | FTDNA}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}